Sterile injectable solutions containing atropine sulfate veterinary-grade API are manufactured for intravenous, intramuscular, and subcutaneous administration during acute organophosphate and carbamate toxicosis in cattle, equine, swine, and companion animals. The finished injection is formulated at 0.54 mg/mL or 1 mg/mL atropine sulfate monohydrate, with sodium chloride 9 mg/mL for isotonicity and pH adjusted to 3.0–3.6 using dilute sulfuric acid; the sulfate salt is selected because atropine base exhibits insufficient aqueous solubility for stable single-phase parenteral products under neutral pH. Compendial compliance is assessed against the USP Atropine Sulfate monograph, the USP Atropine Sulfate Injection monograph, USP <1> Injections and Implanted Drug Products, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins Test, and USP <788> Particulate Matter in Injections. Production-scale multi-purpose stainless steel vessels equipped with bottom-mounted magnetic-drive agitators have shown pH drift after prolonged recirculation through transfer lines because the acidic vehicle can leach trace iron from unpassivated 316L surfaces; passivation and inline pH monitoring with automatic temperature compensation are therefore specified before the API is added. The drug substance is dissolved in cooled water for injection at 20–25 °C under nitrogen overlay, the bulk solution is passed through a 0.22 µm polyethersulfone sterilizing-grade membrane into depyrogenated Type I glass vials, and the filled units are processed in an ISO Class 5 environment under ISO 14644-1 classification. Terminal moist-heat sterilization at 121 °C for 15 min may be validated only when the formulation is stabilised and the pH remains below 4.0; otherwise aseptic filling is used because atropine sulfate undergoes alkaline hydrolysis to tropine and tropic acid with loss of assay as pH rises. Multi-dose rubber-stoppered vials may include benzyl alcohol up to 1.5% v/v as a bacteriostatic agent where permitted for the target species, whereas single-dose vials omit preservatives. Finished pack configurations include 10 mL, 20 mL, and 50 mL vials for veterinary emergency kits and clinical use. The formulation is incompatible with sodium bicarbonate, aminophylline, and barbiturate salts, where immediate precipitation or pH-dependent degradation occurs at the syringe interface. Published data for terminal sterilization of atropine sulfate at high autoclave load density is limited; cycle-specific thermal stability studies are required for each container-closure system prior to routine production.

Why Are Multi-Dose Ophthalmic Solutions Buffered Below pH 4.5?

Atropine sulfate ophthalmic solution is produced as a sterile aqueous preparation for diagnostic mydriasis and cycloplegia in equine recurrent uveitis protocols and in canine and feline ophthalmic examination. The formulation addition ratio is fixed at 10 mg/mL (1% w/v) atropine sulfate monohydrate, with benzalkonium chloride 0.1 mg/mL as preservative and disodium edetate 0.5 mg/mL as chelating aid in a boric acid–borate buffer. The pH is maintained in the range 3.5–4.5 because ester hydrolysis of atropine sulfate follows a pH-dependent pathway, and the degradation rate increases sharply above pH 5.0; storage stability data support acceptable assay retention in the acidic range but not in neutral phosphate-buffered vehicles. Production-scale compounding vessels for ophthalmic solutions require high-torque overhead mixers capable of operating below 500 rpm to avoid vortex-induced foam that occludes the sterilizing-grade filter; a 0.22 µm hydrophilic polyvinylidene fluoride membrane is used after the bulk solution is cooled to 20–25 °C and prefiltered through a 0.45 µm polytetrafluoroethylene membrane. Aseptic filling into low-density polyethylene dropper bottles is conducted in an ISO Class 5 filling zone with hydrogen peroxide-decontaminated transfer isolators; the LDPE containers are pre-sterilised by ethylene oxide or gamma irradiation, and extractable/leachable profiles are monitored because low-pH ophthalmic vehicles may interact with polymer surfaces during shelf life. Terminal product types include multi-dose 5 mL, 10 mL, and 15 mL droptainers and unpreserved single-dose 0.3 mL LDPE units for sterile surgical fields. Compendial compliance includes USP <771> Ophthalmic Preparations—Quality Tests, USP <789> Particulate Matter in Ophthalmic Solutions, USP <71>, and the pH measurement method of USP <791>. Operation above pH 4.5 is not recommended without a validated stabiliser system because tropic acid formation accelerates and the mydriatic response cannot be recovered by reconstitution once hydrolysis has occurred.

Pre-Anaesthetic Injectable Anticholinergic Admixtures

Atropine sulfate injection is used as a pre-anaesthetic anticholinergic in small animal surgical protocols to reduce vagally mediated bradycardia and to dry salivary and bronchial secretions before endotracheal intubation. The terminal product is manufactured at 0.4 mg/mL atropine sulfate in single-use Type I glass ampoules or vials with an osmolality adjusted to 280–300 mOsm/kg; the API addition ratio is 0.4 mg per millilitre of final solution. Compliance is verified under 21 CFR Part 211 subpart F production and process controls, VICH GL11 for stability, and USP <1> for injectable labelling. Filling is conducted at 2–8 °C for temperature-sensitive aseptic processing; tungsten pin failure during ampoule sealing is a documented line stoppage when 1 mL borosilicate ampoules are processed at high speed, requiring optical ampoule inspection for cracks and glass particulates after annealing. Terminal products include 1 mL ampoules and 5 mL multi-dose vials; the 1 mL format supports precise withdrawal for dose calculation at 0.02–0.04 mg/kg in dogs and cats. Atropine sulfate is not added directly to alkaline induction agents such as thiopental sodium in the same syringe because precipitation occurs at the interface.

In companion animal gastroenterology, low-dose atropine sulfate is incorporated into oral combination tablets and capsules used under veterinary supervision for reduction of diarrheal urgency when diphenoxylate hydrochloride is prescribed for canine large-bowel hypermotility. The addition ratio is 0.025 mg atropine sulfate per tablet, typically in a 100 mg core containing diphenoxylate hydrochloride 2.5 mg; the atropine component therefore represents 0.025% w/w of the core weight. Direct compression is preferred over wet granulation because diphenoxylate-containing formulations can generate cohesive agglomerates that adhere to high-shear granulator walls and reduce yield. A 1:100 atropine sulfate-lactose monohydrate trituration is prepared geometrically before addition to the main excipient blend of microcrystalline cellulose and pregelatinized starch. The blend is compressed on a rotary tablet press with a 12-station turret, and the tablets are controlled for hardness in the range 4–6 kp, friability less than 0.8%, and dispersion time not less than 15 min in water at 37 °C. Capsule products are filled on an automatic dosator machine with fill weights of 100 mg; the low API concentration makes content uniformity a critical parameter, and in-process sampling follows USP <905> Uniformity of Dosage Units with stage-wise acceptance criteria. If a dissolution method is required, USP <711> Apparatus 2 at 50 rpm in 0.1 mol/L hydrochloric acid is evaluated because atropine sulfate is freely soluble in acidic aqueous media. Published data for atropine sulfate combination tablets in veterinary species is limited, and assay development must be validated for each tablet or capsule matrix. Terminal product types include scored tablets of 100 mg core mass and hard gelatin capsules of 100 mg fill mass, packaged in amber high-density polyethylene bottles with child-resistant closures.

When Non-Sterile Powder Intermediates Require Geometric Dilution for Extemporaneous Veterinary Compounding

Non-sterile atropine sulfate powder, granule, and premix intermediates are produced for licensed veterinary compounding pharmacies and pharmaceutical manufacturers that compound oral solutions, oral suspensions, and subsequent sterile ophthalmic solutions. The premix intermediate is typically prepared at 0.1% w/w to 1.0% w/w atropine sulfate in anhydrous lactose or spray-dried mannitol, with a 1:10 or 1:100 geometric dilution sequence required before final dispensing. The powder is not suitable for direct administration and is not licensed as a feed premix; published data for atropine sulfate in medicated feed is limited, and such use would require separate residue and safety evaluation by national veterinary regulatory authorities. Compliance for non-sterile intermediates includes USP <795> Pharmaceutical Compounding—Nonsterile Preparations, VICH GL18 residual solvent limits, and 21 CFR Part 211 requirements for components and drug product containers. Blending is performed in tumbling bin blenders or V-blenders operated at low shear; the batch size should not exceed 65% of the blender volume, and blend time is set by blend uniformity analysis rather than a fixed interval because atropine sulfate at low concentration is prone to electrostatic adhesion to stainless steel baffles. The manufacturer's safety data sheet specifies local exhaust ventilation and disposable nitrile double-gloving during weighing and sifting. For granule production, wet granulation is avoided unless a stability study demonstrates no hydrolysis during drying; solvent-free dry granulation with roll compaction at roller pressure 40–60 bar may be used if the resulting granules pass sieve cut 500–1000 µm. Terminal product types include 100 g, 500 g, and 1 kg high-density polyethylene jars of powder trituration, foil-sealed pouches of granulated intermediate, and poly-lined drums of pharmaceutical premix for further dilution. Process controls include moisture content below 4.0% for lactose-based triturations and blend uniformity samples taken at 10 discrete positions per blender charge.